Evaluation of Ocular Sealant for Clear Corneal Wound Closure in Cataract Surgery for High-Risk Patients

Saturday, April 18, 2015: 1:06 PM
Room 5A (San Diego Convention Center)
Cynthia Matossian, MD, FACS

To evaluate the safety of the ReSure Sealant in a high-risk patient population following cataract surgery.

Thirty-four patients (35 eyes) were observed at a single site following clear corneal cataract surgery with phacoemulsification in patients with conditions including diabetes, Graves’ Disease, MRSA, IFIS, Alzheimer’s, Amblyopia, Congenital Cataract, Rheumatoid Arthritis, and patients who received a premium IOL.  The sealant was applied immediately following surgery, and patients were followed for 1 month and observed for IOP, visual acuity, comfort, and adverse ocular events. 

IOP was recorded at 15.74±3.14 at baseline, and 22.06±6.88 and post-op day-1 with no cases of hypotony.  The mean pain score was 0.60±1.18 at day-1, 0.31±0.45 at the 1 week visit, and 0.00 at 1-month (scale of 0-5 with zero being no pain and five representing the worst possible pain).  LogMAR BCVA was 0.22±0.18 at baseline, 0.11±0.14 at 1 week, and 0.06±0.14 at one month.  No device-related adverse events have been noted to date and the study eyes were quiet overall.

A greater likelihood of complications can result from cataract surgery in high-risk patients.  Sutures in these patients are not always ideal due to tissue manipulation, induced astigmatism and the need for later removal.  In this case series, the ReSure Sealant proved safe for clear corneal wound closure use in a high-risk patient population.